EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Lipid-associated sialic acid, squamous cell carcinoma antigen, carcinoembryonic antigen, and lactic dehydrogenase levels as tumor markers in squamous cell carcinoma of the head and neck



Lipid-associated sialic acid, squamous cell carcinoma antigen, carcinoembryonic antigen, and lactic dehydrogenase levels as tumor markers in squamous cell carcinoma of the head and neck



Cancer (philadelphia). 70(10): 2499-2503



Background: Circulating tumor markers are valuable adjuncts in the management of several malignant lesions, including germ cell tumors and adenocarcinomas of the breast, colon, prostate, and ovary. However (to the authors' knowledge), currently, no serologic markers have been shown to have prognostic value for patients with squamous cell carcinomas of the head and neck (SCCHN). Methods: Novel and existing markers were evaluated prospectively in patients with SCCHN. The levels of lipid-associated sialic acids (LASA), squamous cell carcinoma circulating antigen (SCC-Ag), carcinoembryonic antigen (CEA), and lactic dehydrogenase (LDH) were evaluated in 52 patients: 42 with active measurable SCCHN and 10 with no clinical evidence of active disease after treatment (NED). Results: In patients with active disease, LASA, SCC-Ag, CEA, and LDH were elevated in 71%, 33%, 27%, and 18%, respectively, and in seven patients with distant metastasis (M1) in 100%, 86%, 57%, and 33%, respectively. None of the markers were elevated in the NED group. The incidence and magnitude of LASA and SCC-Ag elevations correlated with the extent of disease (active disease versus NED, Stage III versus IV, T0-3 versus T4 primary lesions, M0 versus M1). LDH and CEA elevations correlated primarily with the presence of distant metastases. Conclusions: LASA appears to be a promising sensitive marker of SCCHN, followed in decreasing order of sensitivity by SCC-Ag, CEA, and LDH. Additional study to evaluate the specificity of LASA and its correlation with tumor response to therapy is warranted.

(PDF emailed within 0-6 h: $19.90)

Accession: 008960137

Download citation: RISBibTeXText

PMID: 1423179

DOI: 10.1002/1097-0142(19921115)70:10<2499::aid-cncr2820701018>3.0.co;2-#



Related references

The lack of utility of a tumor marker panel in head and neck carcinoma. Squamous cell carcinoma antigen, carcinoembryonic antigen, lipid-associated sialic acid, and CA-125. Archives of Otolaryngology--Head & Neck Surgery 118(8): 802-805, 1992

Tissue polypeptide antigen, carcinoembryonic antigen, carbohydrate antigen, and CA125 levels as tumor markers in squamous cell carcinoma of the head and neck. Kaohsiung Journal of Medical Sciences 15(3): 152-158, 1999

The significance of ferritin, lipid-associated sialic acid, CEA, squamous cell carcinoma (SCC) antigen, and CYFRA 21-1 levels in SCC of the head and neck. Kulak Burun Bogaz Ihtisas Dergisi 12(1-2): 23-30, 2005

The role of squamous cell carcinoma antigen, ferritin, and carcinoembryonic antigen as serum markers for head and neck tumors. Surgical Forum 44(0): 618-620, 1993

Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer. Journal of Experimental & Clinical Cancer Research 19(4): 477-481, 2001

A study of tumor markers cytokeratin 19 fragment and squamous cell carcinoma-related antigen in squamous cell carcinomas of the head and neck. Yonago Acta Medica 38(3): 205-220, 1995

Serum levels of squamous cell carcinoma antigen and carcinoembryonic antigen as tumor markers of vulvar cancer. Journal of Obstetrics and Gynaecology Research 22(4): 341-346, 1996

Study of new tumor marker, CYFRA 211, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen. Journal Of Nuclear Medicine. 37(5 Suppl.): 145p, 1996

The SCC antigen is not a reliable tumor marker in the ENT area. Value of squamous cell carcinoma antigen in diagnosis and follow-up of squamous epithelial carcinoma in the head-neck area. Results of a retrospective study over 6 years. Laryngo- Rhino- Otologie 77(3): 165-167, 1998

Combination of squamous cell carcinoma-antigen, carcinoembryonic antigen, and carbohydrate antigen 19-9 predicts positive pelvic lymph nodes and parametrial involvement in early stage squamous cell carcinoma of the uterine cervix. Journal of Obstetrics and Gynaecology Research 38(10): 1260-1265, 2013

Relevance of the new tumor marker SCC (squamous cell carcinoma antigen) for the diagnosis and follow-up control of squamous epithelial carcinoma of the head and neck. Hno 37(11): 454-459, 1989

Value of CYFRA 21-1,carcinoembryonic antigen, and squamous cell carcinoma antigen as tumor markers in non-small cell lung cancer patients. Journal of Clinical Oncology 26(15_suppl): 19042-19042, 2016

Squamous cell carcinoma antigen , carcinoembryonic antigen , and tumour-associated trypsin inhibitor for monitoring head and neck cancer. International Journal of Biological Markers 8(2): 81-87, 1993

Squamous cell carcinoma antigen (Scc-Ag): diagnostic utility in squamous cell carcinoma antigen of the head and neck with metastasis to lymph nodes. Otolaryngologia Polska 54 Suppl 31: 203-205, 2000

Squamous cell carcinoma antigen and protein-bound sialic acid in the management of head and neck cancer. International Journal of Biological Markers 6(4): 237-240, 1991